IPO registrations (S-1, F-1) · Registrants
Eiger BioPharmaceuticals, Inc.
- SEC CIK
- 1305253 · filings on EDGAR ↗
- Name on the registration
- Celladon Corp
- Former names
- Celladon Corp (2004–2016)
- Registration
- Form S-1, first filed 2013-10-11, last 2014-08-07; 2 initial registrations, 6 amendments
- Outcome
- Final prospectus filed 2014-01-30; declared effective 2014-01-29
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Business address
- 2155 PARK BOULEVARD, Palo Alto, CA 94306
- EIN
- 36-1004130
- EDGAR entity type
- operating
- Insiders and CEO pay
- Eiger BioPharmaceuticals, Inc. on the corporate pages
Offering terms
- Final price
- $8.00 per share (424B4 filed 2014-01-30, an initial public offering)
- Shares sold
- 5,500,000
- Gross proceeds
- $44,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CLDN
- Lead underwriters
- Barclays
- Syndicate
- Stifel; Wedbush Securities
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: R. R. DONNELLEY & SONS COMPANY EXACT (EIN (EXACT, as the state registration reports it))
- Business registration: EIGER BIOPHARMACEUTICALS INC. Fuzzy (name and state)
- Form 5500 plan sponsor: R. R. DONNELLEY & SONS COMPANY EXACT (EIN (EXACT))
- Federal award recipient: EIGER BIOPHARMACEUTICALS, INC. Fuzzy (name and state)
- Form D issuer: Eiger BioPharmaceuticals, Inc. EXACT (CIK (EXACT))
- Lobbying client: EIGER BIOPHARMACEUTICALS, INC. Fuzzy (name and state)
- SEC filer: Celladon Corp EXACT (CIK (EXACT))
- Person page: Gregg H Alton Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director))
- Person page: Richard A Kayne Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner))
Filings 15
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2013-10-11 | S-1 | S-1 (registration) | Celladon Corp | 0001193125-13-396992 ↗ |
| 2013-10-29 | S-1/A | S-1/A (amendment) | Celladon Corp | 0001193125-13-414057 ↗ |
| 2013-11-01 | S-1/A | S-1/A (amendment) | Celladon Corp | 0001193125-13-421465 ↗ |
| 2013-11-08 | S-1/A | S-1/A (amendment) | Celladon Corp | 0001193125-13-435498 ↗ |
| 2014-01-22 | S-1/A | S-1/A (amendment) | Celladon Corp | 0001193125-14-016605 ↗ |
| 2014-01-28 | S-1/A | S-1/A (amendment) | Celladon Corp | 0001193125-14-022471 ↗ |
| 2014-01-29 | S-1MEF | S-1MEF (added securities) | Celladon Corp | 0001193125-14-027046 ↗ |
| 2014-01-29 | EFFECT | EFFECT (declared effective) | Celladon Corp | 9999999995-14-000243 ↗ |
| 2014-01-30 | 424B4 | 424B4 (final prospectus) | Celladon Corp | 0001193125-14-027264 ↗ |
| 2014-07-30 | S-1 | S-1 (registration) | Celladon Corp | 0001193125-14-285873 ↗ |
| 2014-08-07 | S-1/A | S-1/A (amendment) | Celladon Corp | 0001193125-14-298967 ↗ |
| 2014-08-12 | EFFECT | EFFECT (declared effective) | Celladon Corp | 9999999995-14-002478 ↗ |
| 2014-08-13 | 424B4 | 424B4 (final prospectus) | Celladon Corp | 0001193125-14-307193 ↗ |
| 2016-02-12 | EFFECT | EFFECT (declared effective) | Celladon Corp | 9999999995-16-003755 ↗ |
| 2016-08-04 | EFFECT | EFFECT (declared effective) | Eiger BioPharmaceuticals, Inc. | 9999999995-16-005349 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2014-01-28 | S-1/A | registration statement | $8.00 | 5,000,000 | $40,000,000 | Nasdaq CLDN | 3 | primary document; price sentence, shares headline, proceeds computed, cover names 3 | document ↗ | |
| 2014-01-30 | 424B4 | final prospectus | $8.00 | 5,500,000 | $44,000,000 | Nasdaq CLDN | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| COOPER GRAHAM K | Director | 3 | 2014–2015 | ||
| Dalton Barbara | Director | 1 | 2014 | ||
| Enterprise Partners Liquidating Trust V | TenPercentOwner | 1 | 2014 | ||
| Enterprise Partners Liquidating Trust VI | TenPercentOwner | 1 | 2014 | ||
| Enterprise Partners Management LLC | TenPercentOwner | 2 | 2014 | ||
| Foley Todd | Director | 2 | 2014 | ||
| Funder Joshua | Director | 3 | 2014 | ||
| Kordel Johan | Director | 2 | 2014 | ||
| LABA REBECQUE J | Officer | VP, Corporate Operations; VP Finance & Administration; VP, Finance and Administration | 8 | 2014–2015 | |
| Lundbeckfond Invest A/S | TenPercentOwner | 2 | 2014 | ||
| Novartis Bioventures Ltd | TenPercentOwner | 2 | 2014 | ||
| PFIZER INC | TenPercentOwner | 2 | 2014 | ||
| RUDY JEFFREY J | Officer | VP Clinical Operations; VP, Clinical Operations | 5 | 2014–2015 | |
| TAKEYA RYAN K | Officer | VP Manufacturing; VP, Manufacturing | 6 | 2014–2015 | |
| WIKLUND FREDRIK | Officer | See Remarks; VP Corp Dvlpmnt & Invs Rltns | 4 | 2014–2015 | |
| ZSEBO KRISZTINA M | Director,Officer | Chief Executive Officer; President & CEO | 7 | 2014–2015 | |
| Alton Gregg H | Director | 3 | 2014–2015 | person page Fuzzy | |
| NARACHI MICHAEL | Director | 4 | 2014–2015 | ||
| Honig Peter | Director | 5 | 2014–2015 | ||
| Yang Patrick Y | Director | 3 | 2014 | ||
| REED ELIZABETH E | Officer | VP General Counsel; VP, General Counsel | 3 | 2014–2015 | |
| Cleveland Paul B | Officer | President and CFO | 3 | 2014–2015 | |
| Jackson Andrew C. | Officer | See Remarks | 1 | 2015 | |
| EcoR1 Capital, LLC | TenPercentOwner | 1 | 2015 | ||
| Bramlage Charles | Director | 4 | 2016–2017 | ||
| Dietz Thomas John | Director | 19 | 2016–2023 | ||
| ENGLEMAN EDGAR | Director,TenPercentOwner | 4 | 2016–2017 | ||
| Glenn Jeffrey S | Director | 15 | 2016–2023 | ||
| Martins Eduardo Bruno | Officer | SVP, Liver and Infectious Dise | 4 | 2016–2017 | |
| Quan Joanne | Officer | Chief Medical Officer | 6 | 2016–2018 | |
| Shaffer James P | Officer | Chief Business Officer | 12 | 2016–2021 | |
| WELCH JAMES H | Officer | Chief Financial Officer | 6 | 2016–2018 | |
| Cory David A | Director,Officer | President and CEO | 14 | 2016–2022 | |
| Vivo Ventures Fund VI, L.P. | TenPercentOwner | 2 | 2016 | ||
| VIVO VENTURES VI AFFIILATES FUND, L.P. | Other; TenPercentOwner | 2 | 2016 | ||
| Vivo Ventures VI, LLC | TenPercentOwner | 2 | 2016 | ||
| CLEVELAND BRUCE A | TenPercentOwnerOther | 1 | 2016 | ||
| Desai Keval | TenPercentOwner; TenPercentOwnerOther | 2 | 2016–2018 | ||
| GIANOS PHILIP T | TenPercentOwnerOther | 1 | 2016 | ||
| Holmes W Stephen | TenPercentOwnerOther | 1 | 2016 | ||
| InterWest Management Partners X, LLC | TenPercentOwner; TenPercentOwnerOther | 2 | 2016–2018 | ||
| INTERWEST PARTNERS X LP | TenPercentOwner | 2 | 2016–2018 | ||
| Kjellson Nina S | Director; Director,TenPercentOwner | 4 | 2016–2017 | ||
| Kliman Gilbert H | TenPercentOwner; TenPercentOwnerOther | 2 | 2016–2018 | ||
| NASR KHALED | TenPercentOwner; TenPercentOwnerOther | 2 | 2016–2018 | ||
| ORONSKY ARNOLD L | TenPercentOwner; TenPercentOwnerOther | 2 | 2016–2018 | ||
| Apelian David | Director; Director,Officer | CEO; COO and Ex. Medical Officer; Interim CEO | 11 | 2017–2023 | |
| Loh Evan | Director | 8 | 2017–2023 | ||
| Mayer Eldon C. III | Director; Officer | Ex VP & Chief Commerc. Officer | 17 | 2018–2023 | |
| Kolchinsky Peter | TenPercentOwner | 1 | 2018 | ||
| RA Capital Healthcare Fund LP | TenPercentOwner | 1 | 2018 | ||
| RA CAPITAL MANAGEMENT, LLC | TenPercentOwner | 1 | 2018 | ||
| Ryali Sriram | Officer | Chief Financial Officer | 10 | 2018–2022 | |
| Murray Christine | Director | 8 | 2019–2023 | ||
| Patton Stephana Eilene | Officer | See Remarks | 5 | 2019–2021 | |
| Sachdev Amit | Director | 6 | 2019–2023 | ||
| Sablich Kim | Director | 4 | 2021–2023 | ||
| Atkisson Erik | Officer | GC & Chief Compliance Officer | 4 | 2021–2023 | |
| Kelly-Croswell Lisa | Director | 3 | 2022–2023 | ||
| Kachioff William G | Officer | CFO | 1 | 2023 | |
| Vollins James | Officer | General Counsel | 2 | 2023 | |
| Choong Ingrid | Officer | Chief Business Officer | 2 | 2023 | |
| KAWAS LEEN | TenPercentOwner | 2 | 2023 | ||
| KAYNE RICHARD A | TenPercentOwner | 2 | 2023 | person page Fuzzy |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2016-04-29 | Eiger BioPharmaceuticals, Inc. | Biotechnology | $3,000,000 | $2,999,982 | 1 | 1 |
| 2012-02-06 | Celladon Corp | Biotechnology | $61,349,995 | $17,849,996 | 13 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | EIGER BIOPHARMACEUTICALS INC. | CA | State business registries | name and state |
| Business registration | R. R. DONNELLEY & SONS COMPANY | IL | State business registries | EIN (EXACT, as the state registration reports it) |
| Federal award recipient | EIGER BIOPHARMACEUTICALS, INC. | CA | Federal spending (USAspending) | name and state |
| Form D issuer | Eiger BioPharmaceuticals, Inc. | CA | Form D private offerings | CIK (EXACT) |
| Form D issuer | EIGER BIOPHARMACEUTICALS INC | CA | Form D private offerings | name and state |
| Lobbying client | EIGER BIOPHARMACEUTICALS, INC. | CA | Federal lobbying (LDA) | name and state |
| Paying company | Eiger BioPharmaceuticals, Inc. | CA | Open Payments (drug and device company payments) | name and state |
| Patent assignee | Eiger BioPharmaceuticals, Inc. | CA | Patents (USPTO) | name and state |
| SEC filer | Eiger BioPharmaceuticals, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Eiger BioPharmaceuticals, Inc. | CA | Trademarks (USPTO) | name and state |
| Form 5500 plan sponsor | R. R. DONNELLEY & SONS COMPANY | EIN (EXACT) | ||
| Person page | Gregg H Alton | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (Director) | |
| Person page | Richard A Kayne | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwner) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), CA first:
- SANGAMO THERAPEUTICS, INC CA
- GENITOPE CORP CA
- ABGENIX INC CA
- COLLATERAL THERAPEUTICS INC CA
- Life Technologies Corp CA
- DRUGABUSE SCIENCES INC CA
- STRATAGENE CORP CA
- Cordex Pharma, Inc. CA
- COTHERIX INC CA
- Cardiff Oncology, Inc. CA
In other datasets, the same topic (Health) in CA:
- Nonprofit: 24 HOUR CANCER DANCE-A-THON (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health